RFA-HS-22-008: Diagnostic Centers of Excellence: Partnerships to Improve Diagnostic Safety and Quality (R18)
Closed
This grant is closed. Who won this program's grants before is below, and similar open grants are at the end of the page. It is in our archive of Agency for Health Care Research and Quality notices from 2022.
Agency for Health Care Research and Quality offered grants of up to $4.0 million to nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses. Applications closed on June 9, 2022.
From the official notice on Grants.gov, last changed April 8, 2022. Checked November 7, 2026.
- Award ceiling$4.0 million
- Cost sharingNot required
- Funding typeGrant
Key dates
| Posted | April 7, 2022 |
|---|---|
| Deadline | June 9, 2022 |
| Archived by Grants.gov | July 15, 2022 |
Who can apply
This opportunity was open to nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses.
All 15 applicant types the notice lists
- State governments
- County governments
- City or township governments
- Special district governments
- Independent school districts
- Public and State controlled institutions of higher education
- Native American tribal governments (Federally recognized)
- Public housing authorities/Indian housing authorities
- Native American tribal organizations (other than Federally recognized tribal governments)
- Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
- Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
- Private institutions of higher education
- For profit organizations other than small businesses
- Small businesses
- Others (see text field entitled "Additional Information on Eligibility" for clarification)
Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply.
Is this a realistic fit?
- Past Research on Healthcare Costs, Quality and Outcomes awards averaged $867,535; this notice allows up to $4.0 million per award.
- Most of the program's money (69% over five years) went to colleges and universities.
- No cost sharing or match is required.
What the grant funds
This Notice of Funding Opportunity Announcement (NOFO) invites applications for the development of Diagnostic Centers of Excellence (DCE). The role of a DCE is to support a component of diagnostic care in an integrated cross-disciplinary health system. Each DCE will develop expertise in one or two focus areas of diagnostic improvement. There are four areas of focus. Two of the areas of focus are aligned with frontline diagnostician support: 1) Safety-I error detection and prevention and 2) Safety-II resilience for safe practice Two additional areas of focus are aligned with improving diagnostic systems: 3) improving diagnostic precision through consensus and 4) improving truth or diagnostic reference standards.
Who has won Research on Healthcare Costs, Quality and Outcomes grants before
From fiscal 2021 to 2025, Research on Healthcare Costs, Quality and Outcomes (93.226) awarded $686 million across 791 grant awards, an average of $867,535 per award.
| Recipient | State | Awards | Amount |
|---|---|---|---|
| Regents of the University of Michigan | Michigan | 45 | $46.0 million |
| The Johns Hopkins University | Maryland | 25 | $23.6 million |
| Brigham & Womens Hospital Inc | Massachusetts | 16 | $22.2 million |
| The Regents of the University of California, San Francisco | California | 22 | $19.4 million |
| The Regents of the University of Colorado | Colorado | 23 | $18.5 million |
Applying now
This notice no longer takes applications. Agencies often post the same opportunity again under a new number, so check the program's notices on Grants.gov and the similar open grants below.
The notice on Grants.gov keeps its full text and attachments, which is useful for planning a resubmission.
Questions people ask
Is RFA-HS-22-008 still open?
No. It closed on June 9, 2022.
Who can apply for Diagnostic Centers of Excellence: Partnerships to Improve Diagnostic Safety and Quality (R18)?
Agency for Health Care Research and Quality accepted applications from nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses. The notice adds further conditions, so read its eligibility section.
What is the deadline for Diagnostic Centers of Excellence: Partnerships to Improve Diagnostic Safety and Quality (R18)?
Closed June 9, 2022. Applications are no longer accepted; the program's newer notices are on this page when there are any.
How much funding is available?
Awards of up to $4.0 million each.
Who has won Research on Healthcare Costs, Quality and Outcomes grants before?
The largest recipients over five fiscal years were Regents of the University of Michigan, The Johns Hopkins University, Brigham & Womens Hospital Inc. The program made 791 awards worth $686 million in that time.
Similar open grants
- Single Source for the Continuation of the Caring for OutPatiEnts after Acute Kidney Injury (COPE-AKI) Scientific and Data Research Center (U01 Clinical Trial Required)
- Single Source for the Continuation of the Epidemiology of Diabetes Interventions and Complications (EDIC) Study Research Center (Collaborative U01 Clinical Trial Not Allowed)
- Data Coordinating Center for the Aging and Alzheimer’s Disease Mouse Brain Atlas (AD-MBA) (U24 Clinical Trial Not Allowed)
- Amyotrophic Lateral Sclerosis (ALS) Intermediate Patient Population Expanded Access (U01 Clinical Trial Required)
- Advanced Development and Validation of Emerging Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed)
- Early-Stage Innovative Technology Development for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed)